|
Ahmedabad based Senores Pharmaceuticals Limited has kicked off FY26 on a strong note, reporting robust financial and operational growth across both regulated and emerging markets.
The research-driven pharmaceutical company, known for its focus on specialty and complex products, announced its unaudited results for the quarter ending June 30, 2025.
In the regulated markets, revenue jumped 69% year-on-year to reach Rs. 90 crore, with an impressive EBITDA margin of 35.5%. The company’s portfolio in these markets now includes 24 own commercial products, 70 approved ANDAs, 57 pipeline products with 37 Competitive Generic Therapy (CGT) opportunities, and 27 CDMO/CMO commercial products supported by another 53 in the pipeline.
Emerging markets also maintained a strong trajectory with revenue touching Rs. 29 crore, a 32% increase compared to last year. The EBITDA margin here stood at 6%. Senores’ reach now spans over 40 countries with 308 registered products and 719 under registration.
“Continuing the momentum from last year, we have started FY26 well, with healthy performance across segments during the quarter,” said Swapnil Shah, managing director of Senores Pharmaceuticals. He highlighted that the company launched two own ANDA products and secured four new ANDA approvals in the regulated markets during the quarter.
Shah emphasized the company’s edge in the US market, citing its ability to cater to government channels in addition to the retail segment, as well as its capability to manufacture and supply controlled substances locally. “Our CDMO/CMO segment is also scaling up as planned, with new contracts coming in and increased business from existing customers. The contracts in hand give us good visibility for the year ahead. With our entire formulation manufacturing happening in the US, we remain largely insulated from tariff uncertainties,” he added.
In emerging markets, Senores’ evolving product portfolio and go-to-market strategies are already improving profitability. The branded generics segment is seeing a sharp rise in momentum, with the monthly revenue run rate doubling compared to last year. Shah stated that the company expects to establish a pan-India presence by the end of FY26.
Another highlight of the quarter was the positive operating cash flow of Rs. 11 crore. “Our business is undergoing a structural transformation that will enhance visibility and sustain growth in the medium to long term,” Shah noted. He outlined three focus pillars for the company’s future, expanding the ANDA portfolio in regulated markets, scaling up the CDMO/CMO segment, and strengthening the portfolio and profitability in emerging markets.
Senores Pharmaceuticals is a global, research-led pharma company that develops and manufactures a wide spectrum of products across therapeutic areas for the US, Canada, and over 40 emerging markets.
|